March 1, 2024Journal of Clinical OncologyOpen Access

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

View Full Paper

Ask AI

Bookmark

Authors

ITIng Soo TiongThe University of Melbourne DHDevendra HiwaseRoyal Adelaide Hospital EAEmad AbroThe University of Queensland

Discussion

Member takes

Implication

Prospective phase II trial demonstrates high remission rates with venetoclax and cytarabine in relapsing acute myeloid leukemia, highlighting an effective early salvage strategy.

Key Points

Eradication of measurable residual disease and durable disease control occur with venetoclax plus low-dose cytarabine, inducing high response rates across relapsed cohorts.
Measurable residual disease clearance was achieved by 46% of patients during early treatment, while 73% in the oligoblastic relapse cohort attained complete remission.
Prospective phase II study reveals that venetoclax with low-dose cytarabine is well tolerated, supporting timely molecular intervention before overt clinical relapse occurs.

Cite This Study

Tiong et al. (2024) studied this question.

synapsesocial.com/papers/68e7604eb6db6435876d76de https://doi.org/10.1200/jco.23.01599

View Full Paper

Ask AI

Bookmark

Implication

Prospective phase II trial demonstrates high remission rates with venetoclax and cytarabine in relapsing acute myeloid leukemia, highlighting an effective early salvage strategy.

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Discussion

Member takes

Implication

Key Points

Cite This Study

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider